Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 722 entries
Sorted by: Best Match Show Resources per page
Population statistics and biological traits of endangered kiso horse.

Journal of equine science

Takasu M, Hiramatsu N, Tozaki T, Kakoi H, Hasegawa T, Maeda M, Kusuda S, Doi O, Murase T, Mukoyama H.
PMID: 24833989
J Equine Sci. 2011;22(4):67-72. doi: 10.1294/jes.22.67. Epub 2012 Feb 28.

The objective of this study was to clarify the current status of endangered Kiso horse, population statistics and biological traits, in order to take a step for the conservation by scientific approach. We surveyed 125 Kiso horses (86.2% of...

Cite
Takasu M, Hiramatsu N, Tozaki T, et al. Population statistics and biological traits of endangered kiso horse. J Equine Sci. 2012;22(4):67-72doi: 10.1294/jes.22.67.
Takasu, M., Hiramatsu, N., Tozaki, T., Kakoi, H., Hasegawa, T., Maeda, M., Kusuda, S., Doi, O., Murase, T., & Mukoyama, H. (2011). Population statistics and biological traits of endangered kiso horse. Journal of equine science, 22(4), 67-72. https://doi.org/10.1294/jes.22.67
Takasu, Masaki, et al. "Population statistics and biological traits of endangered kiso horse." Journal of equine science vol. 22,4 (2011): 67-72. doi: https://doi.org/10.1294/jes.22.67
Takasu M, Hiramatsu N, Tozaki T, Kakoi H, Hasegawa T, Maeda M, Kusuda S, Doi O, Murase T, Mukoyama H. Population statistics and biological traits of endangered kiso horse. J Equine Sci. 2011;22(4):67-72. doi: 10.1294/jes.22.67. Epub 2012 Feb 28. PMID: 24833989; PMCID: PMC4013974.
Copy Download .nbib Format: NLM
Hematological and biochemical reference values for the endangered kiso horse.

Journal of equine science

Takasu M, Nagatani N, Tozaki T, Kakoi H, Maeda M, Murase T, Mukoyama H.
PMID: 24834006
J Equine Sci. 2013;24(4):75-8. doi: 10.1294/jes.24.75. Epub 2013 Dec 27.

To establish blood and biochemical references for the endangered Kiso horse, blood samples were collected from 111 adult Kiso horses, 74.5% of the existing breed. The samples were analyzed for 23 hematological and biochemical parameters to determine their means...

Cite
Takasu M, Nagatani N, Tozaki T, et al. Hematological and biochemical reference values for the endangered kiso horse. J Equine Sci. 2013;24(4):75-8doi: 10.1294/jes.24.75.
Takasu, M., Nagatani, N., Tozaki, T., Kakoi, H., Maeda, M., Murase, T., & Mukoyama, H. (2013). Hematological and biochemical reference values for the endangered kiso horse. Journal of equine science, 24(4), 75-8. https://doi.org/10.1294/jes.24.75
Takasu, Masaki, et al. "Hematological and biochemical reference values for the endangered kiso horse." Journal of equine science vol. 24,4 (2013): 75-8. doi: https://doi.org/10.1294/jes.24.75
Takasu M, Nagatani N, Tozaki T, Kakoi H, Maeda M, Murase T, Mukoyama H. Hematological and biochemical reference values for the endangered kiso horse. J Equine Sci. 2013;24(4):75-8. doi: 10.1294/jes.24.75. Epub 2013 Dec 27. PMID: 24834006; PMCID: PMC4013988.
Copy Download .nbib Format: NLM
Electrochemical and catalytic properties of Ni/BaCe0.75Y0.25O3-δ anode for direct ammonia-fueled solid oxide fuel cells.

ACS applied materials & interfaces

Yang J, Molouk AF, Okanishi T, Muroyama H, Matsui T, Eguchi K.
PMID: 25804559
ACS Appl Mater Interfaces. 2015 Apr 08;7(13):7406-12. doi: 10.1021/acsami.5b01048. Epub 2015 Mar 24.

In this study, Ni/BaCe0.75Y0.25O3-δ (Ni/BCY25) was investigated as an anode for direct ammonia-fueled solid oxide fuel cells. The catalytic activity of Ni/BCY25 for ammonia decomposition was found to be remarkably higher than Ni/8 mol % Y2O3-ZrO2 and Ni/Ce0.90Gd0.10O1.95. The...

Cite
Yang J, Molouk AF, Okanishi T, et al. Electrochemical and catalytic properties of Ni/BaCe0.75Y0.25O3-δ anode for direct ammonia-fueled solid oxide fuel cells. ACS Appl Mater Interfaces. 2015;7(13):7406-12doi: 10.1021/acsami.5b01048.
Yang, J., Molouk, A. F., Okanishi, T., Muroyama, H., Matsui, T., & Eguchi, K. (2015). Electrochemical and catalytic properties of Ni/BaCe0.75Y0.25O3-δ anode for direct ammonia-fueled solid oxide fuel cells. ACS applied materials & interfaces, 7(13), 7406-12. https://doi.org/10.1021/acsami.5b01048
Yang, Jun, et al. "Electrochemical and catalytic properties of Ni/BaCe0.75Y0.25O3-δ anode for direct ammonia-fueled solid oxide fuel cells." ACS applied materials & interfaces vol. 7,13 (2015): 7406-12. doi: https://doi.org/10.1021/acsami.5b01048
Yang J, Molouk AF, Okanishi T, Muroyama H, Matsui T, Eguchi K. Electrochemical and catalytic properties of Ni/BaCe0.75Y0.25O3-δ anode for direct ammonia-fueled solid oxide fuel cells. ACS Appl Mater Interfaces. 2015 Apr 08;7(13):7406-12. doi: 10.1021/acsami.5b01048. Epub 2015 Mar 24. PMID: 25804559.
Copy Download .nbib Format: NLM
Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin.

Case reports in gastroenterology

Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O.
PMID: 27721720
Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016.

Direct-acting antivirals (DAAs) are relatively safe and highly effective for the eradication of hepatitis C virus (HCV) in liver transplant recipients. In this case study, we present a female with a graft reinfected with HCV genotype 2 who was...

Cite
Sasaki R, Kanda T, Ohtsuka M, et al. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016;10(2):366-372doi: 10.1159/000447423.
Sasaki, R., Kanda, T., Ohtsuka, M., Yasui, S., Haga, Y., Nakamura, M., Yokoyama, M., Wu, S., Nakamoto, S., Arai, M., Maruyama, H., Miyazaki, M., & Yokosuka, O. (2016). Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case reports in gastroenterology, 10(2), 366-372. https://doi.org/10.1159/000447423
Sasaki, Reina, et al. "Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin." Case reports in gastroenterology vol. 10,2 (2016): 366-372. doi: https://doi.org/10.1159/000447423
Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016. PMID: 27721720; PMCID: PMC5043295.
Copy Download .nbib Format: NLM
A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy.

EJNMMI research

Fujiwara K, Koyama K, Suga K, Ikemura M, Saito Y, Hino A, Iwanari H, Kusano-Arai O, Mitsui K, Kasahara H, Fukayama M, Kodama T, Hamakubo T, Momose T.
PMID: 25006547
EJNMMI Res. 2014 Jun 01;4:29. doi: 10.1186/s13550-014-0029-3. eCollection 2014.

BACKGROUND: ROBO1 is a membrane protein that functions in axon guidance. ROBO1 contributes to tumour metastasis and angiogenesis and may have potential as a target protein of immunotherapy because ROBO1 is specifically expressed at high levels in hepatocellular carcinoma....

Cite
Fujiwara K, Koyama K, Suga K, et al. A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy. EJNMMI Res. 2014;4:29doi: 10.1186/s13550-014-0029-3.
Fujiwara, K., Koyama, K., Suga, K., Ikemura, M., Saito, Y., Hino, A., Iwanari, H., Kusano-Arai, O., Mitsui, K., Kasahara, H., Fukayama, M., Kodama, T., Hamakubo, T., & Momose, T. (2014). A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy. EJNMMI research, 429. https://doi.org/10.1186/s13550-014-0029-3
Fujiwara, Kentaro, et al. "A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy." EJNMMI research vol. 4 (2014): 29. doi: https://doi.org/10.1186/s13550-014-0029-3
Fujiwara K, Koyama K, Suga K, Ikemura M, Saito Y, Hino A, Iwanari H, Kusano-Arai O, Mitsui K, Kasahara H, Fukayama M, Kodama T, Hamakubo T, Momose T. A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy. EJNMMI Res. 2014 Jun 01;4:29. doi: 10.1186/s13550-014-0029-3. eCollection 2014. PMID: 25006547; PMCID: PMC4077627.
Copy Download .nbib Format: NLM
Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Jinnouchi H, Koyama M, Amano A, Takahashi Y, Yoshida A, Hieshima K, Sugiyama S, Kurinami N, Jinnouchi T, Becker R.
PMID: 26055218
Diabetes Ther. 2015 Jun;6(2):143-52. doi: 10.1007/s13300-015-0115-1. Epub 2015 Jun 09.

INTRODUCTION: New insulin glargine 300 U mL(-1) (Gla-300) is a basal insulin that shows more stable and prolonged pharmacokinetic and pharmacodynamic profiles than insulin glargine 100 U mL(-1) (Gla-100). This study used continuous glucose monitoring (CGM) to compare 24-h...

Cite
Jinnouchi H, Koyama M, Amano A, et al. Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study. Diabetes Ther. 2015;6(2):143-52doi: 10.1007/s13300-015-0115-1.
Jinnouchi, H., Koyama, M., Amano, A., Takahashi, Y., Yoshida, A., Hieshima, K., Sugiyama, S., Kurinami, N., Jinnouchi, T., & Becker, R. (2015). Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study. Diabetes therapy : research, treatment and education of diabetes and related disorders, 6(2), 143-52. https://doi.org/10.1007/s13300-015-0115-1
Jinnouchi, Hideaki, et al. "Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 6,2 (2015): 143-52. doi: https://doi.org/10.1007/s13300-015-0115-1
Jinnouchi H, Koyama M, Amano A, Takahashi Y, Yoshida A, Hieshima K, Sugiyama S, Kurinami N, Jinnouchi T, Becker R. Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study. Diabetes Ther. 2015 Jun;6(2):143-52. doi: 10.1007/s13300-015-0115-1. Epub 2015 Jun 09. PMID: 26055218; PMCID: PMC4478173.
Copy Download .nbib Format: NLM
SIRT1 deacetylates RORγt and enhances Th17 cell generation.

The Journal of experimental medicine

Lim HW, Kang SG, Ryu JK, Schilling B, Fei M, Lee IS, Kehasse A, Shirakawa K, Yokoyama M, Schnölzer M, Kasler HG, Kwon HS, Gibson BW, Sato H, Akassoglou K, Xiao C, Littman DR, Ott M, Verdin E.
PMID: 25987725
J Exp Med. 2015 Jun 01;212(6):973. doi: 10.1084/jem.2013237805062015c. Epub 2015 May 18.

No abstract available.

Cite
Lim HW, Kang SG, Ryu JK, et al. SIRT1 deacetylates RORγt and enhances Th17 cell generation. J Exp Med. 2015;212(6):973doi: 10.1084/jem.2013237805062015c.
Lim, H. W., Kang, S. G., Ryu, J. K., Schilling, B., Fei, M., Lee, I. S., Kehasse, A., Shirakawa, K., Yokoyama, M., Schnölzer, M., Kasler, H. G., Kwon, H. S., Gibson, B. W., Sato, H., Akassoglou, K., Xiao, C., Littman, D. R., Ott, M., & Verdin, E. (2015). SIRT1 deacetylates RORγt and enhances Th17 cell generation. The Journal of experimental medicine, 212(6), 973. https://doi.org/10.1084/jem.2013237805062015c
Lim, Hyung W, et al. "SIRT1 deacetylates RORγt and enhances Th17 cell generation." The Journal of experimental medicine vol. 212,6 (2015): 973. doi: https://doi.org/10.1084/jem.2013237805062015c
Lim HW, Kang SG, Ryu JK, Schilling B, Fei M, Lee IS, Kehasse A, Shirakawa K, Yokoyama M, Schnölzer M, Kasler HG, Kwon HS, Gibson BW, Sato H, Akassoglou K, Xiao C, Littman DR, Ott M, Verdin E. SIRT1 deacetylates RORγt and enhances Th17 cell generation. J Exp Med. 2015 Jun 01;212(6):973. doi: 10.1084/jem.2013237805062015c. Epub 2015 May 18. PMID: 25987725; PMCID: PMC4451124.
Copy Download .nbib Format: NLM
Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients.

Journal of arrhythmia

Umei M, Kishi M, Sato T, Shindo A, Toyoda M, Yokoyama M, Matsushita M, Ohnishi S, Yamasaki M.
PMID: 29021853
J Arrhythm. 2017 Oct;33(5):475-482. doi: 10.1016/j.joa.2017.05.008. Epub 2017 Jun 30.

BACKGROUND: Direct oral anticoagulants (DOACs) have been developed for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). We conducted a retrospective cohort study of patients with NVAF who were newly treated with DOACs in a real-world clinical setting.METHODS:...

Cite
Umei M, Kishi M, Sato T, et al. Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. J Arrhythm. 2017;33(5):475-482doi: 10.1016/j.joa.2017.05.008.
Umei, M., Kishi, M., Sato, T., Shindo, A., Toyoda, M., Yokoyama, M., Matsushita, M., Ohnishi, S., & Yamasaki, M. (2017). Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. Journal of arrhythmia, 33(5), 475-482. https://doi.org/10.1016/j.joa.2017.05.008
Umei, Masahiko, et al. "Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients." Journal of arrhythmia vol. 33,5 (2017): 475-482. doi: https://doi.org/10.1016/j.joa.2017.05.008
Umei M, Kishi M, Sato T, Shindo A, Toyoda M, Yokoyama M, Matsushita M, Ohnishi S, Yamasaki M. Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. J Arrhythm. 2017 Oct;33(5):475-482. doi: 10.1016/j.joa.2017.05.008. Epub 2017 Jun 30. PMID: 29021853; PMCID: PMC5634680.
Copy Download .nbib Format: NLM
Image Quality Required for the Diagnosis of Skull Fractures Using Head CT: A Comparison of Conventional and Improved Reconstruction Kernels.

AJNR. American journal of neuroradiology

Takagi S, Koyama M, Hayashi K, Kawauchi T.
PMID: 27418472
AJNR Am J Neuroradiol. 2016 Nov;37(11):1992-1995. doi: 10.3174/ajnr.A4861. Epub 2016 Jul 14.

BACKGROUND AND PURPOSE: Although skull fractures are generally assessed on bone images obtained by using head CT, the combined multikernel technique that enables evaluation of both brain and bone through a change in the window settings of an image...

Cite
Takagi S, Koyama M, Hayashi K, et al. Image Quality Required for the Diagnosis of Skull Fractures Using Head CT: A Comparison of Conventional and Improved Reconstruction Kernels. AJNR Am J Neuroradiol. 2016;37(11):1992-1995doi: 10.3174/ajnr.A4861.
Takagi, S., Koyama, M., Hayashi, K., & Kawauchi, T. (2016). Image Quality Required for the Diagnosis of Skull Fractures Using Head CT: A Comparison of Conventional and Improved Reconstruction Kernels. AJNR. American journal of neuroradiology, 37(11), 1992-1995. https://doi.org/10.3174/ajnr.A4861
Takagi, S, et al. "Image Quality Required for the Diagnosis of Skull Fractures Using Head CT: A Comparison of Conventional and Improved Reconstruction Kernels." AJNR. American journal of neuroradiology vol. 37,11 (2016): 1992-1995. doi: https://doi.org/10.3174/ajnr.A4861
Takagi S, Koyama M, Hayashi K, Kawauchi T. Image Quality Required for the Diagnosis of Skull Fractures Using Head CT: A Comparison of Conventional and Improved Reconstruction Kernels. AJNR Am J Neuroradiol. 2016 Nov;37(11):1992-1995. doi: 10.3174/ajnr.A4861. Epub 2016 Jul 14. PMID: 27418472; PMCID: PMC7963790.
Copy Download .nbib Format: NLM
Histone modification alteration coordinated with acquisition of promoter DNA methylation during Epstein-Barr virus infection.

Oncotarget

Funata S, Matsusaka K, Yamanaka R, Yamamoto S, Okabe A, Fukuyo M, Aburatani H, Fukayama M, Kaneda A.
PMID: 28903418
Oncotarget. 2017 Jul 21;8(33):55265-55279. doi: 10.18632/oncotarget.19423. eCollection 2017 Aug 15.

Aberrant DNA hypermethylation is a major epigenetic mechanism to inactivate tumor suppressor genes in cancer. Epstein-Barr virus positive gastric cancer is the most frequently hypermethylated tumor among human malignancies. Herein, we performed comprehensive analysis of epigenomic alteration during EBV...

Cite
Funata S, Matsusaka K, Yamanaka R, et al. Histone modification alteration coordinated with acquisition of promoter DNA methylation during Epstein-Barr virus infection. Oncotarget. 2017;8(33):55265-55279doi: 10.18632/oncotarget.19423.
Funata, S., Matsusaka, K., Yamanaka, R., Yamamoto, S., Okabe, A., Fukuyo, M., Aburatani, H., Fukayama, M., & Kaneda, A. (2017). Histone modification alteration coordinated with acquisition of promoter DNA methylation during Epstein-Barr virus infection. Oncotarget, 8(33), 55265-55279. https://doi.org/10.18632/oncotarget.19423
Funata, Sayaka, et al. "Histone modification alteration coordinated with acquisition of promoter DNA methylation during Epstein-Barr virus infection." Oncotarget vol. 8,33 (2017): 55265-55279. doi: https://doi.org/10.18632/oncotarget.19423
Funata S, Matsusaka K, Yamanaka R, Yamamoto S, Okabe A, Fukuyo M, Aburatani H, Fukayama M, Kaneda A. Histone modification alteration coordinated with acquisition of promoter DNA methylation during Epstein-Barr virus infection. Oncotarget. 2017 Jul 21;8(33):55265-55279. doi: 10.18632/oncotarget.19423. eCollection 2017 Aug 15. PMID: 28903418; PMCID: PMC5589657.
Copy Download .nbib Format: NLM
Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial.

Nutrition journal

Ohara T, Muroyama K, Yamamoto Y, Murosaki S.
PMID: 28499426
Nutr J. 2017 May 12;16(1):28. doi: 10.1186/s12937-017-0253-6.

No abstract available.

Cite
Ohara T, Muroyama K, Yamamoto Y, et al. Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutr J. 2017;16(1):28doi: 10.1186/s12937-017-0253-6.
Ohara, T., Muroyama, K., Yamamoto, Y., & Murosaki, S. (2017). Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutrition journal, 16(1), 28. https://doi.org/10.1186/s12937-017-0253-6
Ohara, Tatsuya, et al. "Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial." Nutrition journal vol. 16,1 (2017): 28. doi: https://doi.org/10.1186/s12937-017-0253-6
Ohara T, Muroyama K, Yamamoto Y, Murosaki S. Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutr J. 2017 May 12;16(1):28. doi: 10.1186/s12937-017-0253-6. PMID: 28499426; PMCID: PMC5427583.
Copy Download .nbib Format: NLM
Resistive interchange modes destabilized by helically trapped energetic ions in a helical plasma.

Physical review letters

Du XD, Toi K, Osakabe M, Ohdachi S, Ido T, Tanaka K, Yokoyama M, Yoshinuma M, Ogawa K, Watanabe KY, Isobe M, Nagaoka K, Ozaki T, Sakakibara S, Seki R, Shimizu A, Suzuki Y, Tsuchiya H.
PMID: 25933318
Phys Rev Lett. 2015 Apr 17;114(15):155003. doi: 10.1103/PhysRevLett.114.155003. Epub 2015 Apr 17.

A new bursting m=1/n=1 instability (m,n: poloidal and toroidal mode numbers) with rapid frequency chirping down has been observed for the first time in a helical plasma with intense perpendicular neutral beam injection. This is destabilized in the plasma...

Cite
Du XD, Toi K, Osakabe M, et al. Resistive interchange modes destabilized by helically trapped energetic ions in a helical plasma. Phys Rev Lett. 2015;114(15):155003doi: 10.1103/PhysRevLett.114.155003.
Du, X. D., Toi, K., Osakabe, M., Ohdachi, S., Ido, T., Tanaka, K., Yokoyama, M., Yoshinuma, M., Ogawa, K., Watanabe, K. Y., Isobe, M., Nagaoka, K., Ozaki, T., Sakakibara, S., Seki, R., Shimizu, A., Suzuki, Y., Tsuchiya, H. (2015). Resistive interchange modes destabilized by helically trapped energetic ions in a helical plasma. Physical review letters, 114(15), 155003. https://doi.org/10.1103/PhysRevLett.114.155003
Du, X D, et al. "Resistive interchange modes destabilized by helically trapped energetic ions in a helical plasma." Physical review letters vol. 114,15 (2015): 155003. doi: https://doi.org/10.1103/PhysRevLett.114.155003
Du XD, Toi K, Osakabe M, Ohdachi S, Ido T, Tanaka K, Yokoyama M, Yoshinuma M, Ogawa K, Watanabe KY, Isobe M, Nagaoka K, Ozaki T, Sakakibara S, Seki R, Shimizu A, Suzuki Y, Tsuchiya H. Resistive interchange modes destabilized by helically trapped energetic ions in a helical plasma. Phys Rev Lett. 2015 Apr 17;114(15):155003. doi: 10.1103/PhysRevLett.114.155003. Epub 2015 Apr 17. PMID: 25933318.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 722 entries